+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Sirolimus"

Graft versus host disease - Pipeline Insight, 2024 - Product Thumbnail Image

Graft versus host disease - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 220 Pages
  • Global
From
From
From
From
From
2021 Sirolimus Test Volume and Sales Segment Forecasts: US, Europe, Japan - Hospitals, Commercial Labs, POC Locations - Product Thumbnail Image

2021 Sirolimus Test Volume and Sales Segment Forecasts: US, Europe, Japan - Hospitals, Commercial Labs, POC Locations

  • Report
  • March 2021
  • Japan, United States, ... Japan, United States, Europe
From
2020 Sirolimus Test Volume and Sales Forecasts: US, Europe, Japan - Hospitals, Commercial Labs, POC Locations - Product Thumbnail Image

2020 Sirolimus Test Volume and Sales Forecasts: US, Europe, Japan - Hospitals, Commercial Labs, POC Locations

  • Report
  • February 2020
  • Japan, United States, ... Japan, United States, Europe
From
  • 10 Results (Page 1 of 1)
Loading Indicator

Sirolimus, also known as rapamycin, is an immunosuppressive drug used to prevent organ rejection in transplant patients. It works by inhibiting the activity of T-cells, which are responsible for attacking foreign bodies. Sirolimus is also used to treat certain types of cancer, such as lymphoma and Kaposi's sarcoma. It is often used in combination with other immunosuppressive drugs, such as cyclosporine and tacrolimus. Sirolimus is available in both oral and intravenous formulations. It is generally well-tolerated, with the most common side effects being nausea, vomiting, and diarrhea. It is also associated with an increased risk of infection and certain types of cancer. The sirolimus market is highly competitive, with several major players. These include Pfizer, Novartis, Merck, and Astellas. Other companies, such as Mylan and Teva, also offer generic versions of the drug. Show Less Read more